{"id":28967,"date":"2025-07-28T20:03:09","date_gmt":"2025-07-28T20:03:09","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/interventional-robots-rct-research-published-in-jnis-a-leading-journal-in-neurointervention\/"},"modified":"2025-07-28T20:03:09","modified_gmt":"2025-07-28T20:03:09","slug":"interventional-robots-rct-research-published-in-jnis-a-leading-journal-in-neurointervention","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=28967","title":{"rendered":"Interventional Robot’s RCT Research Published in JNIS, a Leading Journal in Neurointervention!"},"content":{"rendered":"

SHANGHAI<\/span><\/span>, July 28, 2025<\/span><\/span> \/PRNewswire\/ — The\u00a0multicenter, randomized controlled trial (RCT) results of the PANVIS-A\u00ae NeuroInterventional Robotic System<\/span>\u2014led by Professor Liu Jianmin<\/span> (Changhai Hospital) in collaboration with Professor Sun Jun<\/span> (Wenzhou Central Hospital), Professor Chen Wenhuo<\/span> (Zhangzhou Municipal Hospital of Fujian Province<\/span>), and Professor Cheng Guangsen (Zhuhai People’s Hospital)\u2014have been officially published in the Journal of NeuroInterventional Surgery (JNIS). This milestone marks the first time a China<\/span>-developed vascular-interventional robot has gained recognition from a premier international neurointerventional journal.<\/p>\n

\n

\"Full<\/a>
Full article: https:\/\/jnis.bmj.com\/content\/early\/2025\/07\/09\/jnis-2025-023412<\/span><\/p>\n<\/div>\n

Registered as NCT05778214, the trial was designed and executed in strict accordance with regulatory guidelines and Good Clinical Practice (GCP). The prospective, multicenter, non-inferiority RCT enrolled 128 patients undergoing diagnostic cerebral angiography (63 randomized to robot assistance, 65 to conventional manual operation). Results demonstrate that PANVIS-A\u00ae is both safe and effective, cutting the primary operator’s radiation exposure by 96% while maintaining procedural performance\u2014offering a revolutionary safeguard for physician occupational health. The system received NMPA market authorization on 23 August 2024<\/span>.<\/p>\n

01 Background: A long-awaited breakthrough for neuro-interventional robotics<\/b><\/p>\n

Traditional neurovascular procedures rely entirely on manual manipulation, exposing operators to chronic radiation and limiting precision. Although robotic systems have entered cardiovascular interventions, neuro-intervention imposes far greater demands\u2014intricate anatomy, tortuous vessels, and operative paths exceeding 70 cm from femoral access to intracranial targets.<\/p>\n

To address this, Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. (abrobo) <\/span>joined forces with leading clinicians to create\u00a0PANVIS-A\u00ae. The platform features the proprietary PANVIS COF\u00ae (Catheter On Finger) fingertip-catheter interface, which replicates combined guidewire rotation and catheter advancement in an intuitive manner. A multi-instrument collaborative drive enables sub-millimetric control over long cerebral trajectories, covering the entire workflow from sheath insertion to final angiographic runs and setting a new benchmark for neuro-interventional robotics.<\/p>\n

02 Study Design: Rigorous multicenter RCT<\/b><\/p>\n

Prospective, multicenter, randomized, non-inferiority trial. Planned enrollment: 130 patients; actual: 128 (robot 63, manual 65). Allocation ratio 1:1.<\/p>\n

\n

\"Figure<\/a>
Figure 2 Randomization and treatment of patients. FAS, full analysis set, PPS, per protocol set.<\/span><\/p>\n<\/div>\n

03 Key Findings: Three major breakthroughs<\/b><\/p>\n

1. Safety & efficacy non-inferior to manual approach<\/p>\n